Amgen Inc. is at least fairly valued, with improving balance sheet metrics and a robust growth pipeline offsetting looming ...

In the last year, many Amgen Inc. (NASDAQ:AMGN) insiders sold a substantial stake in the company which may have sparked ...

The Dow Jones (^DJI) is made up of 30 of the most established and influential companies in the market. But even blue-chip ...

Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.

In a welcome move, Amgen AMGN saw its Relative Strength Rating improve from 66 to 71 on Monday. Please watch the video at Investors.com - How To Trade Options: Choosing The Right Strategy For Best ...

Moat Index gained 1.53% in November, supported by health care and broader market participation. Merck and Amgen were top Moat ...

THOUSAND OAKS, Calif., Dec. 9, 2025 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.52 per share dividend for the first quarter of 2026. The dividend will ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Amgen, with a price target of $385.00. Chen covers the Healthcare sector, focusing on stocks such as Bristol-Myers ...

The Dow Jones index rose Monday. Tesla neared a buy point while President Trump edged closer to a Fed chair pick.

For Immediate Release Chicago, IL – December 9, 2025 – Today, Zacks Equity Research discusses Sandoz SDZNY, Teva ...

UPLIZNA Offers gMG Patients Deep and Durable Symptom Control and Twice-Yearly Dosing* First and Only CD19-Targeted B Cell Therapy Approved in anti-AChR and anti-MuSK ...

It’s an open-ended index fund replicating the Nasdaq 100 Index. With attractive returns clocked by this index attracting ...